These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 30203314)
1. Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients. Fakih R; Matiello M; Chitnis T; Stankiewicz JM J Neurol; 2018 Nov; 265(11):2688-2694. PubMed ID: 30203314 [TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. Michel L; Vukusic S; De Seze J; Ducray F; Ongagna JC; Lefrère F; Jacq-Foucher M; Confavreux C; Wiertlewski S; Laplaud DA J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):279-83. PubMed ID: 23704316 [TBL] [Abstract][Full Text] [Related]
3. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D; Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067 [TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil in the treatment of multiple sclerosis: a preliminary report. Pandit L; Mustafa S; Malli C; D'Cunha A Neurol India; 2014; 62(6):646-8. PubMed ID: 25591678 [TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960 [TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients. Pathomrattanapiban C; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S Mult Scler Relat Disord; 2022 Jul; 63():103882. PubMed ID: 35598463 [TBL] [Abstract][Full Text] [Related]
7. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T; JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762 [TBL] [Abstract][Full Text] [Related]
8. Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis. Davies SL; Moral MA Drug News Perspect; 2006 Dec; 19(10):632-3. PubMed ID: 17299605 [TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China. Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of mycophenolate mofetil in treating neuromyelitis optica spectrum disorder: a multicenter, prospective, self-control study in Guangzhou City]. Huang Q; Wang YG; Shu YQ; Yang H; Wang ZH; Yan ZW; Long YM; Yin J; Feng HY; Li CX; Lu ZZ; Hu XQ; Qiu W Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(21):1664-1668. PubMed ID: 29925143 [No Abstract] [Full Text] [Related]
12. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Songwisit S; Kosiyakul P; Jitprapaikulsan J; Prayoonwiwat N; Ungprasert P; Siritho S Sci Rep; 2020 Oct; 10(1):16727. PubMed ID: 33028926 [TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764 [TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil: An alternative disease-modifying agent for MOG-IgG-associated disorders in childhood: A single-center bidirectional cohort study. Zhou J; Li J; Ren C; Zhou A; Zhuo X; Gong S; Ding C; Fang F; Zhang W; Ren X Mult Scler Relat Disord; 2022 Dec; 68():104128. PubMed ID: 36096009 [TBL] [Abstract][Full Text] [Related]
15. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452 [TBL] [Abstract][Full Text] [Related]
16. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540 [TBL] [Abstract][Full Text] [Related]
17. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917 [TBL] [Abstract][Full Text] [Related]
18. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044 [TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil in paediatric autoimmune or immune-mediated diseases of the central nervous system: clinical experience and recommendations. Nosadini M; Gadian J; Lim M; Sartori S; Thomas T; Dale RC Dev Med Child Neurol; 2019 Apr; 61(4):458-468. PubMed ID: 30221751 [TBL] [Abstract][Full Text] [Related]